Gossamer Bio, Inc.

GOSS

US38341P1021

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.668 ^USD	-0.30%		-14.77%	-26.79%

Mar. 13	Transcript : Gossamer Bio, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM
Mar. 12	Gossamer Bio Announces Board of Directors Appointments	CI

Gossamer Bio, Inc. announced that it has received $211.849524 million in funding from a group of investors

August 06, 2023

On August 7, 2023, Gossamer Bio, Inc. closed the transaction. The transaction included participation from 70 investors.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	FEDERATED HERMES, INC.	32.8 USD	-3.95%	-7.06%	2.63B
	GOSSAMER BIO, INC.	0.668 USD	-0.30%	-14.77%	151M

Latest news about Gossamer Bio, Inc.

Transcript : Gossamer Bio, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM	Mar. 13
Gossamer Bio Announces Board of Directors Appointments	Mar. 12	CI
Goldman Sachs Adjusts Price Target on Gossamer Bio to $8 From $9, Maintains Buy Rating	Mar. 06	MT
Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05	CI
HC Wainwright Adjusts Price Target on Gossamer Bio to $10 From $5, Keeps Buy Rating	Jan. 08	MT
Transcript : Gossamer Bio, Inc. - Special Call	Dec. 18
Gossamer Bio, Inc.(NasdaqGS:GOSS) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Gossamer Bio Inc. Appoints Bob Smith as Chief Commercial Officer	Dec. 05	CI
Gossamer Bio, Inc. Appoints John Quisel to Its Board of Directors	Nov. 29	CI
Wedbush Lifts Gossamer Bio's PT to $6 From $5, Increases Multiple for Seralutinib for Pulmonary Arterial Hypertension in US, EU; Keeps Outperform Rating	Nov. 10	MT
Gossamer Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Gossamer Bio, Inc. Announces Resignation of Kristina Burow from the Board of Directors	23-09-07	CI
Gossamer Bio, Inc. to Present Results of TORREY FRI Sub- Study At the European Respiratory Society International Congress 2023	23-09-07	CI
North American Morning Briefing : China Angst -2-	23-08-15	DJ
Gossamer Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Gossamer Bio, Inc. announced that it has received $211.849524 million in funding from a group of investors	23-08-06	CI
UBS Downgrades Gossamer Bio to Neutral From Buy, Adjusts Price Target to $1.25 From $8	23-07-27	MT
Wedbush Trims Gossamer Bio's Price Target to $5 From $7, Keeps Outperform Rating	23-07-26	MT
Transcript : Gossamer Bio, Inc. - Special Call	23-07-25
Sector Update: Health Care Stocks Gaining Late Thursday	23-07-20	MT
Sector Update: Health Care Stocks Gaining Thursday Afternoon	23-07-20	MT
Gossamer Bio to Sell 129.9 Million Shares, Accompanying Warrants in Private Placement to Raise $212 Million; Shares Fall	23-07-20	MT
Gossamer Bio, Inc.(NasdaqGS:GOSS) dropped from Russell 3000 Index	23-06-23	CI
Gossamer Bio, Inc.(NasdaqGS:GOSS) dropped from Russell Small Cap Completeness Index	23-06-23	CI

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, Î± and Î², as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.668 USD

Average target price

5.719 USD

Spread / Average Target

+756.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GOSSAMER BIO, INC.	-26.79%	151M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research

Gossamer Bio, Inc.

Equities

GOSS

US38341P1021

Biotechnology & Medical Research

Gossamer Bio, Inc. announced that it has received $211.849524 million in funding from a group of investors

Stocks mentioned in the article

Latest news about Gossamer Bio, Inc.

Chart Gossamer Bio, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research